OR8H2: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative diseases

Target Name: OR8H2

NCBI ID: G390151

OR8H2

OR8H2: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative diseases

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease are leading causes of disability and suffering worldwide. These conditions are characterized by progressive loss of brain cells and an increase in the number of neurotransmitter disorders, leading to cognitive decline and motor neuron dysfunction.

Inflammatory neurodegenerative diseases (INNDs) are a subclass of neurodegenerative diseases that involve chronic inflammation of the central nervous system (CNS). These conditions include multiple sclerosis, Guillain-Barre syndrome, and PML, which have a significant impact on patients' quality of life and overall prognosis.

One of the key challenges in the treatment of INNDs is the difficulty in modulating the immune response and reducing inflammation without adverse effects on the nervous system. OR8H2, a protein that is expressed in the brains of individuals with INNDs, has been identified as a potential drug target and biomarker for these conditions.

OR8H2: Structure and Function

OR8H2 is a 21-kDa protein that is expressed in the brains of individuals with INNDs. It is a member of the heat shock protein (HSP) family and is involved in the regulation of protein folding and translation. OR8H2 plays a crucial role in the immune response by regulating the production of pro-inflammatory cytokines.

OR8H2 has been shown to have anti-inflammatory properties in animal models of INNDs. For example, OR8H2 has been shown to reduce the production of pro-inflammatory cytokines such as TNF-alpha, IL-1, and IFN-gamma in rat models of multiple sclerosis and guillain-barre syndrome. OR8H2 also appears to enhance the production of anti-inflammatory cytokines such as IL-10 in these models.

OR8H2 has also been shown to have neuroprotective properties in animal models of INNDs. For example, OR8H2 has been shown to protect dopamine-dependent neurons from neurotoxicity in rat models of Parkinson's disease. OR8H2 also appears to promote the survival of glial cells in the central nervous system, which are important for the support of nerve cells.

Drug Targeting

OR8H2 is a potential drug target for INLDs because of its anti-inflammatory and neuroprotective properties. Drugs that can modulate the activity of OR8H2, such as inhibitors of the production of pro-inflammatory cytokines, may be effective in treating INLDs. Additionally, drugs that can enhance the activity of OR8H2, such as those that promote its expression or function, may also be effective in treating INLDs.

Biomarker

OR8H2 has also been identified as a potential biomarker for INLDs. The levels of OR8H2 have been shown to be decreased in the brains of individuals with INLDs, and its levels have been correlated with the severity of the disease. Additionally, the levels of OR8H2 have been shown to be sensitive to therapeutic intervention, with levels increasing in individuals with INLDs treated with anti-inflammatory drugs.

Conclusion

OR8H2 is a protein that has been identified as a potential drug target and biomarker for INLDs. Its anti-inflammatory and neuroprotective properties make it a promising target for the development of new treatments for these conditions. Further research is needed to fully understand the role of OR8H2 in INLDs and to develop safe and effective treatments.

Protein Name: Olfactory Receptor Family 8 Subfamily H Member 2

Functions: Odorant receptor

The "OR8H2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR8H2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets